MediCrops offers its customers premium quality and dependable products based on a highly integrated production process and strict product quality standards
We are continuously striving to become the leading producer of THC-based medicinal cannabis products in the German-speaking region in Europe, while at the same time improving the quality and efficiency of our distribution network in Europe.
Our ambition is to deliver consistent quality to every customer. Our standardised processes, production methods and in-house research and development are the tools for fulfilling our mission.
For this purpose, we are building the most modern high-tech production facility together with our certified partners in Switzerland. The traceability of our value chain provides our customers with complete transparency.
We develop personalised therapy solutions for our patients based on our product portfolio, such as patented ready-to-use medicines, inhalants and extracts from our own production.
With the legalisation of cannabis, a new industry is emerging in Europe with huge growth potential and economic returns that will benefit all MediCrops stakeholders.
Profitable growth for all shareholders
The global medicinal cannabis market is estimated to grow at an average of 12.2% per year between 2021-2026.
On the international stock markets, cannabis is the second big growth story after Blockchain for investors looking for investment opportunities in a low-interest environment. Moreover, the health sector, like the pharmaceutical sector, is favoured by investors and is considered a ‘safe haven’, especially if the stock market environment should become more volatile.
Investors have been part of the growth story at MediCrops from the very beginning and benefit from an above-average return in one of the world’s largest growth markets.
Future viability is our recipe for success
We position ourselves as a first-class B2B supplier of medicinal cannabis to the pharmaceutical industry.
We cover all tasks from logistics to production and service in our value creation process and are creating our own research and development department in collaboration with the University of Lausanne. The highest quality based on the pharmaceutical industry (EU-GMP guidelines) and proof of laboratory work to achieve a high purity level is the primary objective to ensure successful audits for our customers.
That is why a holistic management concept that takes into account the interests of our shareholders, customers, suppliers and employees in equal measure is crucial for us.
MediCrops at work – ‘Our team is your team’
We have many years of experience in building international corporate structures, processes and strategy development in the pharmaceutical, agricultural and business sectors and have a large network in the industry and the financial market. Our successful track record and commitment to our shareholders continue to drive us on: ‘There’s a lot to do – we’re getting on with it’.
Switzerland has a lot of locational advantages to offer
Political reform is underway. There are numerous private investors – politicians, athletes, family offices – who invest money in cannabis projects and there are top universities with corresponding research projects, such as the University of Lausanne with which MediCrops is already working.
Attractive business location with a future:
MediCrops has its headquarters in Freienbach in the low-tax canton of Schwyz, and together with one of the leading general planners, IE Life Science Engineering AG, is building one of the world’s most state-of-the-art facilities near Lausanne in Yverdon-les-Bains in the Y-Parc technology centre to enable the production and development of THC drugs.
We design our operations and supply chain in line with the goals of the Paris Climate Agreement and keep greenhouse gas emissions to a minimum from the outset.
In this way, we comply with the sustainability requirements within the legal framework in order to simultaneously achieve our ecological and economic goals with a higher production volume at lower costs and thus maximise a sustainable profit.
Pragmatic action for moral purposes
We act according to the categorical imperative because our maxim is to improve the lives of many people for the common good.
Our business model is aligned with social responsibility and economic efficiency. Our corporate governance, which is ethically sound and at the same time pragmatic, is committed to ensuring the highest quality of our products and increases both moral acceptance and economic success for the benefit of our patients and investors.